Treatment of chronic liver disease with ursodeoxycholic acid.
Evidence is accumulating that ursodeoxycholic acid (UDCA), an agent widely employed for gallstone dissolution, exerts therapeutic effects in chronic liver disease. UDCA is thought to act mainly by reducing the detergent properties of bile, making it less toxic for the liver cells. Confirming the results of preliminary observations double-blind, placebo-controlled trials have shown that UDCA significantly decreased serum concentrations of liver enzymes such as alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and gamma-glutamyl transferase in primary biliary cirrhosis and other cholestatic conditions, as well as in chronic active hepatitis. A substantial improvement in liver histology has also been detected in UDCA-treated patients with primary biliary cirrhosis. The effect of UDCA in chronic hepatitis is currently a matter of investigation.
Guslandi
M
M
Institute of Internal Medicine, University of Milan, Italy.
D002779:Cholestasis / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000188:drug therapy* / Q000378:metabolism; D008111:Liver Function Tests; D014580:Ursodeoxycholic Acid / Q000378:metabolism / Q000627:therapeutic use*
D014580:Ursodeoxycholic Acid